9 2019 INTEGRATED SUMMARY REPORT Phase 3 Regulatory Review NME NME Tirzepatide Diabetes Ultra-Rapid Lispro Diabetes Lebrikizumab (IL-13 mAb) Atopic Flortaucipir Tau Imaging, Dermatitis diagnostic Mirikizumab Psoriasis Selpercatinib RET fusion & Solanezumab Alzheimer’s RET mutant cancers NILEX Tanezumab Osteoarthritis Pain Empagliflozin Chronic Kidney Disease NILEX Empagliflozin Heart Failure Dulaglutide 3.0/4.5 mg Diabetes Tirzepatide Obesity Connected Care Diabetes Baricitinib Alopecia Areata Prefilled Insulin Pen Baricitinib Systemic Lupus Empagliflozin Type 1 Diabetes Erythematosus Baricitinib Atopic Dermatitis Mirikizumab Ulcerative Colitis Ixekizumab Non-Radiographic Mirikizumab Crohn’s Disease AxSpA Abemaciclib Adjuvant Breast Ixekizumab Pediatric Psoriasis Cancer Selpercatinib 1L NSCLC Selpercatinib 1L Medullary Thyroid Cancer Tanezumab Cancer Pain DIABETES IMMUNOLOGY NEURODEGENERATION ONCOLOGY PAIN Ultra-Rapid Lispro (URLi) Mirikizumab A novel, fast-acting mealtime insulin lispro for adults with type 1 and An IL-23 antibody that could transform the treatment of ulcerative type 2 diabetes. It’s designed to more closely mirror the way insulin colitis and Crohn’s disease and is also being studied to advance the works in people without diabetes. Lilly has received a positive opinion treatment of psoriasis. from regulators in Europe and has submitted URLi for regulatory approval in the U.S. and Japan.